AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04785833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T cell injection targeting CD7 chimeric antigen receptor
Description: Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
Study NCT06529081 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy
Description: Standard treatment with added consolidative radiotherapy to the chest area and possibly metastatic lesions (if indicated) in doses and for palliative indications (total dose of 30 Gy in 10 daily doses of 3 Gy each).
Study NCT06529081 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical/Ablative Radiotherapy
Description: Standard treatment with added radical/ablative radiotherapy (total dose of 45 Gy in 15 daily fractions of 3 Gy to the chest area and total dose of 24 Gy administered in single fractions of 8 Gy every 2-3 days to the metastatic lesions) to the chest area and all metastatic lesions.
Study NCT04608084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma eye drops
Description: Participant own blood is used for the preparation of Autologous platelet rich plasma eye drops
Study NCT05751083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brisk walk+ low intensity aerobic exercises
Description: Brisk Walking Protocol General flexibility Exercises Protocol Chair Sitting~1. Extending leg up then down~2. Raising up then down on toes later heels~3. Marching in place~4. Bringing leg to sideway then back towards middle~5. Bringing leg towards chair then forward~6. Bend arms up towards shoulders then back down again.~7. Pushing arms away from chest then back~8. Pushing arm up from shoulders then back down~9. Raising shoulders towards ears then back down~10. Rolling shoulders forward and backward~11. Raising arm at shoulder levels and extend forearm upward towards ceiling then back down~12. Bringing elbows inwards and outwards from chest Standing Balance Exercises
Study NCT05751083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brisk walk
Description: Brisk Walking Protocol~The brisk walking protocol will consist of :~1. 10 min: warming up of the knees, hips and back by flexibility exercises~2. 30 min of walking~3. 5 min of cool down.
Study NCT05771116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:
Description: catheter will be placed for ERECTOR SPINAE PLANE BLOCK
Study NCT05771116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PARAVERTEBRAL BLOCK:
Description: catheter will be placed for PARAVERTEBRAL BLOCK
Study NCT04745676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Telehealth ACP intervention advance care planning intervention
Study NCT04617028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Jaktinib Hydrochloride Tablets administered orally twice daily
Study NCT04617028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Hydroxycarbamide
Description: Placebo to match Hydroxycarbamide Tablets administered orally twice daily
Study NCT04617028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycarbamide Tablets
Description: Hydroxycarbamide Tablets administered orally twice daily
Study NCT04617028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match Jaktinib
Description: Placebo to match Jaktinib Tablets administered orally twice daily
Study NCT06272734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reprieve System
Description: The study is broken into stages:~1. In Stage one, Subjects enrolled in the study received Reprieve System (RS) therapy, a hospital bedside fluid management system designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure. (complete, N=10)~2. In future Stages, Subjects enrolled in the study will receive RS therapy and will be given varying levels of water consumption to challenge the algorithm. Future Stages will also assess new RS hardware and software features.
Study NCT06164262 — intervention group
Intervention type: OTHER
Intervention: Individuals with CSVD
Description: This does not entail the application of interventions.
Study NCT06412276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Food menu will be provided as is typical for the out of home outlet
Study NCT06412276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Product price promotions removed
Description: Food menus with no price reductions to products
Study NCT06412276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bulk buy reductions removed
Description: Food menus with bundles provided but not at reduced prices
Study NCT06412276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volume value pricing removed
Description: Food menus with proportionate pricing for multi-size products
Study NCT06412276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No price-based incentives
Description: Food menus with no price-based incentives offered
Study NCT05132699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) oral solution
Description: An oral strawberry flavored liquid, taken as a 2.5ml (250mg) dose twice a day
Study NCT05132699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inert strawberry flavored oral solution, taken as a 2.5ml dose twice a day
Study NCT05735782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome
Description: Evaluation of persistent symptoms of COVID-19 and its association with psychological, cognitive and social status in comparison to a healthy control group
Study NCT05735782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome
Description: Determine the inflammatory, immune profile and ventricular function in post-COVID-19 participants compared to a control group
Study NCT05955170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib in Combination of Oral VP16 and trastuzumab
Description: Combination of tucatinib-Oral VP16-trastuzumab
Study NCT05423691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK0804
Description: CK0804 is a cryopreserved, allogeneic T-regulatory cell product that is manipulated to traffic to the bone marrow.
Study NCT05132699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Massed Prolonged Exposure (mPE)
Description: mPE, delivered daily Monday through Friday over two weeks, utilizes exposure-based interventions to target psychological mechanisms (i.e., experiential and behavioral avoidance; maladaptive cognitive changes) that are thought to maintain trauma-related symptoms.
Study NCT05132699 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Massed Prolonged Exposure (mPE)
Description: mPE, delivered daily Monday through Friday over two weeks, utilizes exposure-based interventions to target psychological mechanisms (i.e., experiential and behavioral avoidance; maladaptive cognitive changes) that are thought to maintain trauma-related symptoms.
Study NCT06190899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib is a potent reversible inhibitor that selectively targets all Class I PI3K isoforms and mTOR.
Study NCT06190899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide is a novel androgen receptor inhibitor that has been studied and received approval for treatment of patients with nonmetastatic CRPC and in metastatic hormone-sensitive prostate cancer.
Study NCT04965402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days
Study NCT04965402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT06541717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Based Fertility Awareness Training
Description: Students will be shown 3 15-minute videos created by researchers on the anatomy and physiology of the male and female reproductive systems, the physiology of pregnancy, fertility awareness development and its importance in terms of infertility.
Study NCT06303882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
Study NCT06303882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation treatment
Description: The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
Study NCT06303882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted Cognitive Function Training
Description: Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
Study NCT06303882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional cognitive training
Description: including Memory training, attention training, and executive function training were conducted 2-5 times per week, lasting for 30-60 minutes each session, based on the patient's condition.
Study NCT06538129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypersensitivity prevention protocol with Er:YAG laser
Description: 1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using visual analogue scale (VAS); 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade,); 4.Placement of dental dam followed by photoactivation with Valo cordless curing light 5.Hypersensitivity prevention protocol with Er:YAG laser in cervical region (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital immediately after bleaching, 48 after bleaching and one week after bleaching.
Study NCT06538129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypersensitivity prevention protocol with neutral sodium fluoride gel
Description: 1.Prophylaxis using airflow system with erythritol, potency 5, water regulator 5; 2.Initial assessment of hypersensitivity using the VAS; 3.Color assessment (canines, central incisors and lateral incisors) with digital spectrophotometer (Vita Easyshade); 4.Placement of dental dam followed by photoactivation with Valo cordless; 5.Hypersensitivity prevention protocol with neutral sodium fluoride gel for 4 minutes (central incisor, lateral incisor and canine); 6.Application of whitening gel (1 mm in thickness) with 35% hydrogen peroxide on maxillary arch (Clareador Whiteness HP; FGM), left to react for 15 minutes; 7.Removal of whitening gel; 8.Repeat procedures (steps 7 and 8); 9.Assessment of hypersensitivity immediately after hypersensitivity prevention procedure, immediately after bleaching, 48 after bleaching and one week after bleaching; 10.Color assessment with digital spectrophotometer immediately after bleaching, 48 after bleaching and one week after bleaching.
Study NCT05440864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Pre-operatively Tremelimumab will be administered first for 1 hour; the Durvalumab infusion (1hr) will start approximately 1 hour (maximum 2 hours) after the end of the Tremelimumab infusion. Post-operatively patients will receive Durvalumab Q4W to complete up to 12 months of treatment or a maximum of 11 cycles of adjuvant Durvalumab
Study NCT06669065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extraoral versus intraoral scanning techniques
Description: different data acquisition techniques for full-arch dental implants
Study NCT06669130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xiangtong TM full degradation sinus drug stent system
Description: use Xiangtong TM full degradation sinus drug stent system to deliver drugs into sinus
Study NCT06669130 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: nasopore
Description: use nasopore to protect the post-operative sinus
Study NCT06669637 — intervention group
Intervention type: DEVICE
Intervention: Ablation
Description: Ablation procedure for Atrial Fibrillation
Study NCT05045664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Rituximab with 12 x 2 Gy involved site radiotherapy
Study NCT05045664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Obinutuzumab with 2 x2 Gy involved site radiotherapy
Study NCT06470347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy
Description: During treatment, subjects were given 400 mg pyrrotinib once daily, within 30 minutes after breakfast.
Study NCT05646602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Clostridium Histolyticum
Description: Intralesional injection
Study NCT05646602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: Intralesional injection
Study NCT05646602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duolith SD1 T-TOP
Description: Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz
Study NCT05646602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duolith SD1 T-TOP
Description: Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz
Study NCT05190900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neural mobilization
Description: neural mobilisation of the posterior tibial, deep peroneal and lateral, intermediate and medial dorsocutaneous nerves.
Study NCT05250947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel® Concentrated Platelet Rich Plasma System
Description: Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP.
Study NCT05250947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: 6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint
Study NCT05492019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 50 mg capsule twice daily for 8 weeks.
Study NCT05492019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo identical to Doxycycline
Study NCT05052515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts
Description: Patients with NAFLD will be randomly allocated to receive Choline - Vitamin C, E and Ampelopsis Grossedentata natural extracts supplementation
Study NCT05052515 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with NAFLD will be randomly allocated to receive placebo
Study NCT06669000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard X-Rays
Description: - Standard X-Rays: feet (Month 0)
Study NCT06669000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: - Ultrasound (score 0-24): assessment for DC (Double Contour) sign (0-3), aggregates (0-3), tophi (0-3) at MTP1s (first metatarsophalangeal joints) and DC sign (0-3) at both knees, according to the OMERACT, every 6 months until complete dissolution of urate deposits.
Study NCT06669000 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DECT of feet
Description: DECT of feet: in tophaceous patients only (Month 0, Month 24)
Study NCT05430568 — intervention group
Intervention type: PROCEDURE
Intervention: robot-assisted surgery
Description: 1. traditional sternotomy for coronary bypass graft or valvular replacement~2. robot-assisted surgery for coronary bypass graft or valvular replacement
Study NCT05504616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health technology-based intervention strategy
Description: Patient-centered, technology-based intervention strategy aimed at increasing physical activity in patients with axSpA
Study NCT06045975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
Description: * Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by IRE procedure at Day 30+/-7 days~* 11 monthly Durvalumab 1500 mg infusions.
Study NCT06456398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Through a randomized controlled trial, educational training will be designed, and pre- and post-tests will be conducted to compare the effectiveness of learning advanced anatomy using the Metaverse Virtual 3D Printing System in virtual reality, versus the traditional method of using flat diagrams to correlate with computed tomography scans.
Study NCT06669000 — intervention group
Intervention type: BIOLOGICAL
Intervention: DNA sample
Description: DNA will be collected at Month 0
Study NCT06669000 — intervention group
Intervention type: BIOLOGICAL
Intervention: Serum collection
Description: - Serum will be collected at Month 0, Month 6, Month 12, Month 18, Month 24 , Month 36 and Month 48. For OMICs and epigenetic studies: Month 0, Month 6, Month 24 and Month 36.
Study NCT06670911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Pembrolizumab Plus Chemotherapy (Paclitaxel plus Carboplatin or Cisplatin)
Description: Patients will receive pembrolizumab 100mg IV every 3 weeks plus chemotherapy (paclitaxel 175 mg/m² + carboplatin AUC 5 or paclitaxel 175 mg/m² + cisplatin 50 mg/m² for cisplatin-naïve patients).
Study NCT05261100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises
Description: Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercises will be performed along with core stability exercises..
Study NCT05261100 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercise perform.
Study NCT06626191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Interscalene brachial plexus block will be performed on the patients using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study NCT06626191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus posterior superior intercostal plane block
Description: Patients will undergo serratus posterior superior intercostal plane block using 30 ml of local anesthetic solution (0.25% bupivacaine) under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study NCT04728737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: swallowing therapy
Description: oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
Study NCT04728737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: swallowing therapy
Description: oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
Study NCT04745455 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Infant formula containing prebiotics, probiotics and postbiotics
Description: Infant formula containing prebiotics, probiotics and postbiotics